Investors Buy Large Volume of Recursion Pharmaceuticals Call Options (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) was the target of unusually large options trading activity on Wednesday. Stock traders purchased 33,531 call options on the stock. This is an increase of 180% compared to the typical volume of 11,957 call options.

Analyst Ratings Changes

A number of brokerages recently weighed in on RXRX. KeyCorp reduced their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research report on Wednesday, January 8th. Needham & Company LLC reiterated a "buy" rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $8.75.

Recursion Pharmaceuticals Price Performance

RXRX stock traded up $0.61 during trading on Wednesday, reaching $7.49. 36,378,055 shares of the company were exchanged, compared to its average volume of 16,558,314. The company has a market cap of $2.93 billion, a P/E ratio of -4.90 and a beta of 0.85. Recursion Pharmaceuticals has a 52-week low of $5.60 and a 52-week high of $15.74. The stock's 50 day moving average price is $6.86 and its 200 day moving average price is $6.94. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business had revenue of $26.08 million during the quarter, compared to analysts' expectations of $12.62 million. During the same period last year, the company earned ($0.43) EPS. The firm's revenue for the quarter was up 147.6% on a year-over-year basis. As a group, analysts predict that Recursion Pharmaceuticals will post -1.56 earnings per share for the current fiscal year.

Insider Transactions at Recursion Pharmaceuticals

In related news, Director Blake Borgeson sold 11,447 shares of the business's stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $6.72, for a total value of $76,923.84. Following the completion of the sale, the director now directly owns 7,077,560 shares of the company's stock, valued at $47,561,203.20. The trade was a 0.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Michael Secora sold 15,000 shares of the business's stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total transaction of $114,900.00. Following the completion of the sale, the chief financial officer now directly owns 1,499,631 shares of the company's stock, valued at approximately $11,487,173.46. This trade represents a 0.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 43,894 shares of company stock valued at $317,139. Insiders own 15.75% of the company's stock.

Institutional Trading of Recursion Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. Allspring Global Investments Holdings LLC purchased a new position in shares of Recursion Pharmaceuticals during the third quarter valued at approximately $25,000. Decker Retirement Planning Inc. purchased a new position in shares of Recursion Pharmaceuticals during the fourth quarter valued at approximately $26,000. GAMMA Investing LLC increased its position in Recursion Pharmaceuticals by 1,979.2% during the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock worth $35,000 after purchasing an additional 4,948 shares during the last quarter. Farther Finance Advisors LLC increased its position in Recursion Pharmaceuticals by 176.9% during the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company's stock worth $42,000 after purchasing an additional 4,091 shares during the last quarter. Finally, KBC Group NV increased its position in Recursion Pharmaceuticals by 79.9% during the third quarter. KBC Group NV now owns 7,602 shares of the company's stock worth $50,000 after purchasing an additional 3,377 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company's stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.